Evidence map›Paper›PMID 37269217›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2024

Impact of Nanomedicine in Women's Metastatic Breast Cancer.

Ali Akbar Ashkarran, Zijin Lin, Jatin Rana, Harvey Bumpers, Lorenzo Sempere, Morteza Mahmoudi

Open access · hybridAbstract readReview
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ali Akbar AshkarranDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Zijin LinDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Jatin RanaDivision of Hematology and Oncology, Michigan State University, East Lansing, MI, 48824, USA.
Harvey BumpersDepartment of Surgery, Michigan State University, East Lansing, MI, 48824, USA.
Lorenzo SempereDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Morteza MahmoudiDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.ORCID 0000-0002-2575-9684
Michigan State University · USBrigham and Women's Hospital · US

Funding

Image-Guided Intraductal Ablative Procedure for Primary Prevention of Breast CancerR01CA258314 · NCI · MICHIGAN STATE UNIVERSITY · PI Lorenzo Sempere · 2022 to 2026
$2.8M
A Nanostructured Skin Patch to Heal Chronic WoundsR01DK131417 · NIDDK · MICHIGAN STATE UNIVERSITY · PI Morteza Mahmoudi · 2022 to 2026
$2.0M
NCI NIH HHS R01 CA258314NIDDK NIH HHS R01 DK131417NIH HHS CA258314NIH HHS DK131417
6 · The paper itself

Abstract

Metastatic breast cancer is responsible for 90% of mortalities among women suffering from various types of breast cancers. Traditional cancer treatments such as chemotherapy and radiation therapy can cause significant side effects and may not be effective in many cases. However, recent advances in nanomedicine have shown great promise in the treatment of metastatic breast cancer. For example, nanomedicine demonstrated robust capacity in detection of metastatic cancers at early stages (i.e., before the metastatic cells leave the initial tumor site), which gives clinicians a timely option to change their treatment process (for example, instead of endocrine therapy they may use chemotherapy). Here recent advances in nanomedicine technology in the identification and treatment of metastatic breast cancers are reviewed.

Indexed as

Breast NeoplasmsNanomedicineNeoplasm MetastasisFemaleHumansbiomarkerearly detectionmetastatic breast cancernanomedicinewomen health

Identifiers

PMID37269217
PMCPMC10693652
OpenAlexW4379197674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.